CA2445049A1 - Rapidly cleavable sumo fusion protein expression system for difficult to express proteins - Google Patents
Rapidly cleavable sumo fusion protein expression system for difficult to express proteins Download PDFInfo
- Publication number
- CA2445049A1 CA2445049A1 CA002445049A CA2445049A CA2445049A1 CA 2445049 A1 CA2445049 A1 CA 2445049A1 CA 002445049 A CA002445049 A CA 002445049A CA 2445049 A CA2445049 A CA 2445049A CA 2445049 A1 CA2445049 A1 CA 2445049A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- recombinant
- protease
- poly
- ulp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000014509 gene expression Effects 0.000 title claims description 69
- 108020001507 fusion proteins Proteins 0.000 title claims description 50
- 102000037865 fusion proteins Human genes 0.000 title claims description 49
- 108090000623 proteins and genes Proteins 0.000 title description 47
- 102000004169 proteins and genes Human genes 0.000 title description 43
- 150000001413 amino acids Chemical class 0.000 claims description 88
- 239000012634 fragment Substances 0.000 claims description 58
- 108091005804 Peptidases Proteins 0.000 claims description 55
- 239000004365 Protease Substances 0.000 claims description 55
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 51
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 49
- 238000000746 purification Methods 0.000 claims description 48
- 238000003776 cleavage reaction Methods 0.000 claims description 44
- 230000007017 scission Effects 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 37
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 36
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 36
- 230000002708 enhancing effect Effects 0.000 claims description 30
- 108010018628 Ulp1 protease Proteins 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 238000010367 cloning Methods 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 18
- 238000003259 recombinant expression Methods 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 108091008146 restriction endonucleases Proteins 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 102000002933 Thioredoxin Human genes 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 108060008226 thioredoxin Proteins 0.000 claims description 6
- 229940094937 thioredoxin Drugs 0.000 claims description 6
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 5
- 229920002704 polyhistidine Polymers 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 2
- 101000684503 Homo sapiens Sentrin-specific protease 3 Proteins 0.000 claims 17
- 102100023645 Sentrin-specific protease 3 Human genes 0.000 claims 17
- 102000051619 SUMO-1 Human genes 0.000 claims 5
- 108700038981 SUMO-1 Proteins 0.000 claims 3
- 101000879203 Caenorhabditis elegans Small ubiquitin-related modifier Proteins 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 230000004927 fusion Effects 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 17
- 101100095557 Caenorhabditis elegans ulp-1 gene Proteins 0.000 description 14
- 108091022894 CDPdiacylglycerol-Serine O-Phosphatidyltransferase Proteins 0.000 description 12
- 101150091206 Nfkbia gene Proteins 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 101150102102 SMT3 gene Proteins 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 102000044159 Ubiquitin Human genes 0.000 description 4
- 108090000848 Ubiquitin Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 101100478890 Caenorhabditis elegans smo-1 gene Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 3
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 101150096255 SUMO1 gene Proteins 0.000 description 3
- 101100408688 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmt3 gene Proteins 0.000 description 3
- 101710183280 Topoisomerase Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108010037870 Anthranilate Synthase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- PWBJWDKDPAPGED-UHFFFAOYSA-N n'-chlorobutanediamide Chemical compound NC(=O)CCC(=O)NCl PWBJWDKDPAPGED-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- 108700004676 Bence Jones Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108030003004 Triphosphatases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000017730 intein-mediated protein splicing Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28865601P | 2001-05-04 | 2001-05-04 | |
| US60/288,656 | 2001-05-04 | ||
| US32908001P | 2001-10-12 | 2001-10-12 | |
| US60/329,080 | 2001-10-12 | ||
| PCT/US2002/014062 WO2002090495A2 (en) | 2001-05-04 | 2002-05-06 | Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2445049A1 true CA2445049A1 (en) | 2002-11-14 |
Family
ID=26965151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002445049A Abandoned CA2445049A1 (en) | 2001-05-04 | 2002-05-06 | Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6872551B2 (enExample) |
| EP (1) | EP1392717B1 (enExample) |
| JP (1) | JP2004532033A (enExample) |
| AT (1) | ATE490968T1 (enExample) |
| AU (1) | AU2002257243A1 (enExample) |
| CA (1) | CA2445049A1 (enExample) |
| DE (1) | DE60238532D1 (enExample) |
| WO (1) | WO2002090495A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103184228A (zh) * | 2011-12-29 | 2013-07-03 | 天津市国际生物医药联合研究院 | 用于可结晶成熟型SARS冠状病毒非结构蛋白12(sars-nsp12)的外源重组表达及纯化方法 |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596527B1 (en) * | 1999-07-31 | 2003-07-22 | Board Of Regents, The University Of Texas Sytem | Composition and methods relating to SENP 1- a sentrin-specific protease |
| US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| WO2002090495A2 (en) * | 2001-05-04 | 2002-11-14 | Cornell Research Foundation, Inc. | Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
| US8535908B2 (en) * | 2002-01-04 | 2013-09-17 | Brookhaven Science Associates, Llc | Facilitating protein solubility by use of peptide extensions |
| US7220576B2 (en) * | 2002-01-07 | 2007-05-22 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| JP2005514025A (ja) | 2002-01-07 | 2005-05-19 | ライフセンサーズ、インク． | タンパク質発現及び精製のための方法及び組成 |
| JP2005532829A (ja) * | 2002-07-18 | 2005-11-04 | インヴィトロジェン コーポレーション | 組換え部位を含むウイルスベクター |
| WO2004063214A2 (en) * | 2003-01-08 | 2004-07-29 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Antibodies that specifically recognize sumo-conjugated proteins |
| JP2007529191A (ja) * | 2003-06-26 | 2007-10-25 | ライフセンサーズ、インク． | タンパク質発現を増強し、精製する方法及び組成物 |
| WO2005014796A2 (en) | 2003-08-08 | 2005-02-17 | Invitrogen Corporation | Methods and compositions for seamless cloning of nucleic acid molecules |
| US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| CA2543257C (en) | 2003-10-24 | 2013-12-31 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| US8304189B2 (en) | 2003-12-01 | 2012-11-06 | Life Technologies Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
| ES2306541B1 (es) * | 2004-04-16 | 2009-09-28 | Consejo Superior Investig. Cientificas | Trasplante funcional de la maquinaria de sumoilacion a escherichia coli. |
| EP1791961B1 (en) * | 2004-08-18 | 2011-06-08 | The Governors of the University of Alberta | Protein production method utilizing yebf |
| US8119369B2 (en) * | 2004-12-30 | 2012-02-21 | Lifesensors, Inc. | Human SUMO-3 for enhancing protein expression |
| CA2670014A1 (en) * | 2006-11-22 | 2008-11-20 | Emory University | Production of anti-microbial peptides |
| EP2100961A1 (en) * | 2008-03-04 | 2009-09-16 | Icon Genetics GmbH | Method of protease production in plants |
| US20090280531A1 (en) * | 2008-05-06 | 2009-11-12 | Academia Sinica | Preparation of Soluble Capsid Proteins of Picornaviruses Using SUMO Fusion Technology |
| TW200951219A (en) * | 2008-05-06 | 2009-12-16 | Academia Sinica | An improved SUMO fusion protein system for effective production of native proteins |
| US8440449B2 (en) * | 2008-09-30 | 2013-05-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Transformed Saccharomyces cerevisiae engineered for xylose utilization |
| US8663951B2 (en) * | 2009-01-09 | 2014-03-04 | Academia Sinica | Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system |
| CN102533712A (zh) * | 2009-05-12 | 2012-07-04 | 中国科学院上海生命科学研究院 | 一种固相化sumo化系统及固相化去sumo化系统 |
| CN101993495B (zh) * | 2009-08-12 | 2013-07-24 | 上海近岸科技有限公司 | 一种蛋白质混合物及其制备方法 |
| WO2013103972A1 (en) | 2012-01-06 | 2013-07-11 | Gencia Corporation | Treatment of frailty syndrome and symptoms thereof |
| US20160038565A1 (en) | 2012-06-15 | 2016-02-11 | Gencia Corporation | Methods of Mitigating Side Effects of Radiation Exposure and Chemotherapy |
| WO2013188873A1 (en) | 2012-06-15 | 2013-12-19 | Gencia Corporation | Compositions and methods for enhancing immune responses |
| CA2885931C (en) | 2012-10-03 | 2023-01-10 | Agrivida, Inc. | Intein-modified proteases, their production and industrial applications |
| KR101911438B1 (ko) | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법 |
| WO2014144017A2 (en) | 2013-03-15 | 2014-09-18 | Gencia Corporation | Compositions and methods for treating conditions that affect epidermis |
| US9970945B2 (en) | 2013-06-07 | 2018-05-15 | Georgia State University Research Foundtion, Inc. | Compositions, methods, and assays using proteo-liposome-transfected oocytes for analyzing the structure, function, and activity of membrane proteins |
| US9447157B2 (en) | 2013-09-13 | 2016-09-20 | Augusta University Research Institute, Inc. | Nitration shielding peptides and methods of use thereof |
| WO2015049230A1 (en) | 2013-10-01 | 2015-04-09 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | An orthogonal set of tag-cleaving proteases for purification of proteins and stoichiometric protein complexes |
| US10378003B2 (en) | 2014-11-10 | 2019-08-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tag removal from proteins expressed in pro- and eukaryotic hosts |
| MA56219A (fr) * | 2015-10-14 | 2022-04-20 | Translate Bio Inc | Modification d'enzymes apparentées à l'arn pour une production améliorée |
| TWI591177B (zh) * | 2016-10-27 | 2017-07-11 | 中化合成生技股份有限公司 | 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法 |
| US10913777B2 (en) | 2017-05-22 | 2021-02-09 | The Regents Of The University Of California | In vitro assembly of bacterial microcompartments |
| BR112020004389A2 (pt) | 2017-09-06 | 2020-09-08 | Yale University | composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo. |
| KR20190135393A (ko) * | 2018-05-28 | 2019-12-06 | 주식회사 원진바이오테크놀로지 | 폴리유비퀴틴 스캐폴드에 결합된 생체분자들의 선형 멀티머 중합체 및 이의 용도 |
| CN109517074A (zh) * | 2018-12-04 | 2019-03-26 | 湖北大学 | 一种融合标签促进Kuma030蛋白酶可溶性表达及非亲和层析快速纯化的应用 |
| CN109628479A (zh) * | 2018-12-25 | 2019-04-16 | 天津农学院 | 一种胰高血糖素样肽-1的重组表达方法 |
| WO2020142720A1 (en) * | 2019-01-04 | 2020-07-09 | Cogen Immune Medicine, Inc. | Methods of producing high diversity peptide libraries and promoting protein folding |
| CN113025675B (zh) * | 2021-05-21 | 2021-08-20 | 凯莱英医药集团（天津）股份有限公司 | 多肽的制备方法 |
| CN118695869A (zh) | 2022-02-14 | 2024-09-24 | 佐治亚大学研究基金会股份有限公司 | 泛-肺病毒疫苗组合物及其使用方法 |
| CN114426586A (zh) * | 2022-02-21 | 2022-05-03 | 中国农业大学 | 一种胞外分泌表达Ulp1蛋白酶的大肠杆菌基因工程菌株及其应用 |
| CN114539425B (zh) * | 2022-02-25 | 2023-04-28 | 湖南中晟全肽生化有限公司 | 一种提高线性多肽生物表达的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132213A (en) * | 1986-10-02 | 1992-07-21 | Massachusetts Institute Of Technology | Method for producing proteins and polypeptides using ubiquitin fusions |
| US5643758A (en) * | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| WO1997001627A1 (en) * | 1995-06-27 | 1997-01-16 | Igen International, Inc. | High-level expression and efficient recovery of ubiquitin fusion proteins from escherichia coli |
| WO2002090495A2 (en) * | 2001-05-04 | 2002-11-14 | Cornell Research Foundation, Inc. | Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
| JP2005514025A (ja) * | 2002-01-07 | 2005-05-19 | ライフセンサーズ、インク． | タンパク質発現及び精製のための方法及び組成 |
-
2002
- 2002-05-06 WO PCT/US2002/014062 patent/WO2002090495A2/en not_active Ceased
- 2002-05-06 AU AU2002257243A patent/AU2002257243A1/en not_active Abandoned
- 2002-05-06 DE DE60238532T patent/DE60238532D1/de not_active Expired - Lifetime
- 2002-05-06 JP JP2002587558A patent/JP2004532033A/ja active Pending
- 2002-05-06 EP EP02726837A patent/EP1392717B1/en not_active Expired - Lifetime
- 2002-05-06 CA CA002445049A patent/CA2445049A1/en not_active Abandoned
- 2002-05-06 AT AT02726837T patent/ATE490968T1/de not_active IP Right Cessation
- 2002-07-02 US US10/188,343 patent/US6872551B2/en not_active Expired - Lifetime
-
2004
- 2004-09-24 US US10/949,685 patent/US7498165B2/en not_active Expired - Fee Related
-
2008
- 2008-10-10 US US12/249,334 patent/US7910364B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103184228A (zh) * | 2011-12-29 | 2013-07-03 | 天津市国际生物医药联合研究院 | 用于可结晶成熟型SARS冠状病毒非结构蛋白12(sars-nsp12)的外源重组表达及纯化方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US6872551B2 (en) | 2005-03-29 |
| US7498165B2 (en) | 2009-03-03 |
| DE60238532D1 (de) | 2011-01-20 |
| EP1392717A4 (en) | 2005-06-08 |
| AU2002257243A1 (en) | 2002-11-18 |
| US7910364B2 (en) | 2011-03-22 |
| WO2002090495A8 (en) | 2003-07-03 |
| ATE490968T1 (de) | 2010-12-15 |
| JP2004532033A (ja) | 2004-10-21 |
| EP1392717B1 (en) | 2010-12-08 |
| US20030086918A1 (en) | 2003-05-08 |
| EP1392717A1 (en) | 2004-03-03 |
| US20050069988A1 (en) | 2005-03-31 |
| WO2002090495A2 (en) | 2002-11-14 |
| US20090317868A1 (en) | 2009-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7498165B2 (en) | Rapidly cleavable SUMO fusion protein expression system for difficult to express proteins | |
| Catanzariti et al. | An efficient system for high‐level expression and easy purification of authentic recombinant proteins | |
| US5506121A (en) | Fusion peptides with binding activity for streptavidin | |
| Young et al. | Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications | |
| US7655413B2 (en) | Methods and compositions for enhanced protein expression and purification | |
| JP4377242B2 (ja) | ビオチン化ドメインを含むタンパク質タグ、及び溶解性を増大させる方法、及び折り畳み状態を決定する方法 | |
| US20190292535A1 (en) | Nucleic acids encoding chimeric polypeptides for library screening | |
| US5935823A (en) | Totally synthetic affinity reagents | |
| JP2005516074A6 (ja) | ビオチン化ドメインを含むタンパク質タグ、及び溶解性を増大させる方法、及び折り畳み状態を決定する方法 | |
| AU2003238441A1 (en) | Protein tag comprising a biotinylation domain and method for increasing solubility and determining folding state | |
| US7220576B2 (en) | Methods and compositions for protein expression and purification | |
| CA2376062A1 (en) | Fusion proteins comprising a fragment of a chaperon polypeptide | |
| JP4749548B2 (ja) | インテイン媒介ペプチド連結 | |
| US20070275416A1 (en) | Affinity marker for purification of proteins | |
| JP2012525143A (ja) | 不溶性の組み換えタンパク質に対して溶解性を付与する新規な融合タグ | |
| CN101172996A (zh) | 用于多肽融合表达的连接肽及多肽融合表达方法 | |
| EP1981978B1 (en) | Affinity polypeptide for purification of recombinant proteins | |
| Kang et al. | Heterologous expression and optimized one-step separation of levansucrase via elastin-like polypeptides tagging system | |
| CN111662388A (zh) | 一种蛋白质表达纯化的方法 | |
| US20050106671A1 (en) | Expression vector, host cell and method for producing fusion proteins | |
| Cole et al. | Gene expression and tagging of streptococcal proteins | |
| US20110177615A1 (en) | Protein expression | |
| HK1128727B (en) | Chimaeric fusion protein with superior chaperone and folding activities | |
| HK1128727A1 (en) | Chimaeric fusion protein with superior chaperone and folding activities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140506 |